Novo Nordisk's weight-loss drug Wegovy has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease characterized by moderate to advanced liver fibrosis without cirrhosis. This marks the first glucagon-like peptide-1 (GLP-1) therapy approved for MASH, unlocking a potential market valued at approximately $30 billion. Following the FDA clearance, Novo Nordisk's shares rose by up to 7%, recovering some losses from recent weeks. Concurrently, Novo Nordisk announced a substantial reduction in the price of its diabetes drug Ozempic for cash-paying patients in the United States, cutting the monthly cost to $499—about half of the previous list price of $1,350. This offer is available through Novo's NovoCare pharmacy, a new partnership with telehealth service GoodRx, and other platforms, expanding access to Ozempic and Wegovy for uninsured or self-paying patients. GoodRx's shares surged over 29% on the news of the collaboration. The price reduction and expanded FDA indications come amid ongoing discussions about high drug prices in the U.S. and efforts to improve affordability and market access for these GLP-1 therapies.